

2019/10/24

Company:	CYBERDYNE, INC.
Name of Representative:	Yoshiyuki Sankai, President and CEO
Code:	7779 (Mothers Section of the Tokyo Stock Exchange)
Contact:	Shinji Uga, Director and CFO (Tel. +81-29-869-9981)

### **Notice on consigned research and development agreement with AMED to promote clinical trial of small size HAL towards patient with cerebral palsy**

A joint proposal of CYBERDYNE, INC. (the “Company”) and University of Tsukuba (Representative Organization of Research and Development) was adopted by Japan Agency for Medical Research and Development (“AMED”) for its solicited project “Clinical Trial/ Clinical Researches to Actualize a Medical Device for Children”. The Company have entered into a consigned research and development agreement with AMED following the adoption.

1. Name of the project  
“Project to Develop and Conduct Investigator Initiated Clinical Trial of Wearable Treatment Robot for Lower Limb Designed to Improve the Motor Function of Children with Developmental Stage Non-Progressive Motor Dysfunction such as Cerebral Palsy” (Lead Investigator: Aiki Marushima University of Tsukuba, Faculty of Medicine)
2. Detail of shared research and development task  
Development of device for clinical trial following the result, safety information and information of malfunction upon clinical research on adolescent with cerebral palsy using HAL S Size and children with cerebral palsy using HAL 2S Size. The Company will also develop a device for clinical trial according to prior consultation and advices received from the Pharmaceuticals and Medical Devices Agency of Japan, in line with the strategy of pharmaceutical affairs.
3. Period  
Consigned period: From the sign date of the contract until March 31, 2020.  
Scheduled period of entire R&D : From the sign date of the contract until March 31, 2024.
4. Scheduled amount of consigned research and development expenses  
¥23.6 million yen (The amount of expenses for the next fiscal year and onwards will be determined according to the research and development plan for each fiscal year). The exact amount will be settled after the examination which will take place after the conclusion of consigned period.
5. Future prospects  
The relevant consigned research and development expenses is planned for posting in the consolidated financial statement of profit and loss for fiscal year ending March 31, 2020 as “other income”.